Merck vaccine trial delayed
Exclusive: Merck vaccine case linked to HHS Secretary Kennedy delayed mid-trial
Merck and a woman suing the drugmaker agreed to halt a trial over alleged injuries from the drugmaker's human papillomavirus vaccine in a case with ties to U.S. Department of Health and Human Services Secretary Robert F.
Merck & Co. has penned a $300 million biobucks-per-product deal with cancer biotech Epitopea to identify previously secret ...
Germany's Merck KGaA said on Tuesday its lab equipment division and its pharmaceuticals division would be under new ...
NEW YORK, NY / ACCESS Newswire / February 19, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn ...
The FDA has authorized ImmunityBio’s expanded access program to bring alternative sources of the cancer-fighting bacteria BCG ...
Gilead (GILD) stock won an upgrade from Deutsche Bank on HIV treatment boost, while Merck (MRK) stock received a downgrade on ...
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $112.46, a high ...
Merck KGaA said it’s in advanced talks to purchase SpringWorks Therapeutics Inc., sending shares of the US cancer and rare ...
Big Tech and pharmaceutical companies are accelerating the implementation of artificial intelligence in the healthcare ...
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback